Stanford University
Showing 1-10 of 510 Results
-
Franz Ake
Postdoctoral Scholar, Pathology
BioDr. Ake is a computational biologist specializing in single-cell transcriptomics, alternative polyadenylation, and isoform regulation. His research focuses on developing computational methods and bioinformatic pipelines to characterize post-transcriptional regulation and differential isoform usage at single-cell resolution. During his PhD under the mentorship of Dr. Mireya Plass at the University of Barcelona and the IDIBELL Research Institute in Barcelona, Spain, he developed approaches for isoform quantification and the analysis of differential isoform usage in single-cell datasets.
Currently, his research at Stanford University focuses on multi-omics data integration, with a particular emphasis on spatial transcriptomics and cancer genomics to study tumor biology, tissue heterogeneity, and disease-associated molecular programs from high-dimensional sequencing data. -
Kimberly Allison
Professor of Pathology
Current Research and Scholarly InterestsDr. AllisonÂ’s clinical expertise is in breast pathology. Her research interests include how standards should be applied to breast cancer diagnostics (such as ER and HER2 testing), the utility of molecular panel-based testing in breast cancer, digital pathology applications and identifying the most appropriate management of specific pathologic diagnoses.
-
Michael Angelo
Associate Professor of Pathology
BioMichael Angelo, MD PhD is a board-certified pathologist and assistant professor in the department of Pathology at Stanford University School of Medicine. Dr. Angelo is a leader in high dimensional imaging with expertise in tissue homeostasis, tumor immunology, and infectious disease. His lab has pioneered the construction and development of Multiplexed Ion Beam Imaging by time of flight (MIBI-TOF). MIBI-TOF uses secondary ion mass spectrometry and metal-tagged antibodies to achieve rapid, simultaneous imaging of dozens of proteins at subcellular resolution. In recognition of this achievement, Dr. Angelo received the NIH Director’s Early Independence award in 2014. His lab has since used this novel technology to discover previously unknown rule sets governing the spatial organization and cellular composition of immune, stromal, and tumor cells within the tumor microenvironment in triple negative breast cancer. These findings were found to be predictive of single cell expression of several immunotherapy drug targets and of 10-year overall survival. This effort has led to ongoing work aimed at elucidating structural mechanisms in the TME that promote recruitment of cancer associated fibroblasts, tumor associated macrophages, and extracellular matrix remodeling. Dr. Angelo is the recipient of the 2020 DOD Era of Hope Award and a principal investigator on multiple extramural awards from the National Cancer Institute, Breast Cancer Research Foundation, Parker Institute for Cancer Immunotherapy, the Bill and Melinda Gates Foundation, and the Human Biomolecular Atlas (HuBMAP) initiative.
